The longer the osteoporosis medication is stopped, the lower the risk of developing jawbone necrosis
Jul 03, 2025
If osteoporosis patients stop taking injectable bisphosphonate used to treat osteoporosis before dental treatment for a certain period of time, the risk of developing drug-related jawbone necrosis (MRONJ)' is reduced, according to a study.
A research team led by Park Jung-hyun, a professor of oral and maxillofacial surgery at Ewha Womans University Mokdong Hospital, analyzed more than 150,000 osteoporosis patients in Korea to confirm the relationship between the duration of discontinuation of osteoporosis injection and the risk of MRONJ.
The research team conducted the study by dividing the duration of osteoporosis drugs into four groups with different administration periods. Group A stopped administering drugs for less than 90 days, Group B 91 to 180 days, Group C 181 to 365 days, and Group D stopped administering drugs for more than 365 days. As a result, the risk of developing MRONJ decreased by 43% in group B, 55% in group B, and 57% in group C compared to group A.
Until now, clinical evidence has been insufficient as to whether discontinuing drugs in osteoporosis patients lowers the incidence of MRONJ.
In this study, it was confirmed that the longer the period of discontinuation of osteoporosis drugs before dental treatment in osteoporosis patients, the lower the incidence of MRONJ, suggesting that it is a new option in the future treatment process.
MRONJ is a disease caused by long-term use of certain drugs such as osteoporosis drugs and anticancer drugs, and when it occurs, it causes serious side effects such as mastication disorders and facial deformation as well as necrosis and pain of the jawbone. In particular, the risk is known to increase significantly after invasive procedures such as extraction or implants.
Professor Park "This study is not only meaningful in implementing big data collected in the actual medical environment in Korea, but is also expected to contribute to preparing practical clinical guidelines for MRONJ prevention in the future.""Not only is jawbone necrosis difficult to treat once it occurs, but it also has a significant impact on the patient's daily life, so patients taking osteoporosis drugs must consult a doctor before dental treatment to determine when and how long to stop the drug.'
Currently, Professor Park Jung-hyun is conducting active multidisciplinary research with the aim of identifying the mechanism of development of axillary necrosis, developing and standardizing treatments, and establishing disease management guidelines at the Intractable Axial Necrosis Clinical Research Center at Ewha Womans University Mokdong Hospital.
Meanwhile, this study was conducted with Professor Park Jung-hyun of oral and maxillofacial surgery at Ewha Womans University Mokdong Hospital (joint author) and Professor Gong Sung-hye of the Department of Endocrine Metabolism at Bundang Seoul National University Hospital (joint author), and the research paper was published in the international journal Nature Communications (IF 16.6).
A research team led by Park Jung-hyun, a professor of oral and maxillofacial surgery at Ewha Womans University Mokdong Hospital, analyzed more than 150,000 osteoporosis patients in Korea to confirm the relationship between the duration of discontinuation of osteoporosis injection and the risk of MRONJ.
The research team conducted the study by dividing the duration of osteoporosis drugs into four groups with different administration periods. Group A stopped administering drugs for less than 90 days, Group B 91 to 180 days, Group C 181 to 365 days, and Group D stopped administering drugs for more than 365 days. As a result, the risk of developing MRONJ decreased by 43% in group B, 55% in group B, and 57% in group C compared to group A.
Until now, clinical evidence has been insufficient as to whether discontinuing drugs in osteoporosis patients lowers the incidence of MRONJ.
In this study, it was confirmed that the longer the period of discontinuation of osteoporosis drugs before dental treatment in osteoporosis patients, the lower the incidence of MRONJ, suggesting that it is a new option in the future treatment process.
MRONJ is a disease caused by long-term use of certain drugs such as osteoporosis drugs and anticancer drugs, and when it occurs, it causes serious side effects such as mastication disorders and facial deformation as well as necrosis and pain of the jawbone. In particular, the risk is known to increase significantly after invasive procedures such as extraction or implants.
Professor Park "This study is not only meaningful in implementing big data collected in the actual medical environment in Korea, but is also expected to contribute to preparing practical clinical guidelines for MRONJ prevention in the future.""Not only is jawbone necrosis difficult to treat once it occurs, but it also has a significant impact on the patient's daily life, so patients taking osteoporosis drugs must consult a doctor before dental treatment to determine when and how long to stop the drug.'
Currently, Professor Park Jung-hyun is conducting active multidisciplinary research with the aim of identifying the mechanism of development of axillary necrosis, developing and standardizing treatments, and establishing disease management guidelines at the Intractable Axial Necrosis Clinical Research Center at Ewha Womans University Mokdong Hospital.
Meanwhile, this study was conducted with Professor Park Jung-hyun of oral and maxillofacial surgery at Ewha Womans University Mokdong Hospital (joint author) and Professor Gong Sung-hye of the Department of Endocrine Metabolism at Bundang Seoul National University Hospital (joint author), and the research paper was published in the international journal Nature Communications (IF 16.6).
|
This article was translated by Naver AI translator.
